RxDoctor Payments Data

Dennis Liu, MD

Rheumatology · Folsom, CANPI 1366554933

Payments from drug & device makers

$1,096in general payments, 2019–2025

Across 30 payments — averaging $36.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$308
  • Novartis$306
  • Sanofi$145
  • UCB, Inc.$125
  • Johnson & Johnson$89
  • GSK$47
  • plus $76 from 3 others

What the payments were for

  • Food & beverage$1,04695%
  • Education$505%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,096 in reported general payments places this provider in the 40th percentile of 808 rheumatology providers in California.

See all rheumatology providers in California

Medicare billing

Part B allowed, 2024
$120,486
Medicare patients
289
Services billed
1,888

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab132$1,087,669
Enbrel SureclickEtanercept88$695,656
Cosentyx Sensoready PenSecukinumab50$376,334
Orencia ClickjectAbatacept46$323,287
Cosentyx Sensoready (2 Pens)Secukinumab40$305,421
RinvoqUpadacitinib16$181,451
Taltz AutoinjectorIxekizumab14$141,757
Cimzia (2 Pack)Certolizumab Pegol15$136,937
BenlystaBelimumab21$95,047
SimponiGolimumab13$76,861
Actemra ActpenTocilizumab13$52,821
Leucovorin Calcium232$33,090
Leflunomide280$23,205
Azathioprine235$20,053
Hydroxychloroquine Sulfate248$13,688

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$308$181,45116 claims
UCB, Inc.Cimzia (2 Pack)$125$136,93715 claims
GSKBenlysta$47$95,04721 claims
Johnson & JohnsonSimponi$89$76,86113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 808 rheumatology providers in California.

Other rheumatology in Folsom

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →